Bioavailability Study Comparing 2 Vamifeport Oral Formulations in Fasted Versus Fed State in Healthy Subjects
A Randomised, Open-Label, Food Effect and Formulation Bioavailability Study of Two Vamifeport Oral Formulations in Healthy Male and Female Adults
Sponsor: Vifor (International) Inc.
Listed as NCT05077436, this PHASE1 trial focuses on Healthy and remains completed. Sponsored by Vifor (International) Inc., it has been updated 7 times since 2021, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Sep 2022 — Jul 2024 [monthly]
Completed PHASE1
-
May 2022 — Sep 2022 [monthly]
Completed PHASE1
-
Feb 2022 — May 2022 [monthly]
Completed PHASE1
Status: Recruiting → Completed
▶ Show 2 earlier versions
-
Dec 2021 — Feb 2022 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Nov 2021 — Dec 2021 [monthly]
Not Yet Recruiting PHASE1
First recorded
Oct 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Vifor (International) Inc.
For direct contact, visit the study record on ClinicalTrials.gov .